Literature DB >> 15662134

Paraneoplastic leukemoid reaction and rapid progression in a patient with malignant melanoma: establishment of KT293, a novel G-CSF-secreting melanoma cell line.

Bodo Schniewind1, Matthias Christgen, Axel Hauschild, Roland Kurdow, Holger Kalthoff, Hans Jürgen Klomp.   

Abstract

Paraneoplastic leukemoid reaction (PLR) is a rare condition of leucocytosis in cancer patients. Here we report the rapid progression of a patient suffering from a metastasized malignant melanoma and PLR. The patient's white blood cell count exceeded 200,000 cells per mul and the serum level of Granulocyte Colony-Stimulating Factor (G-CSF) was elevated up to 780 pg/mul. A Tc-m99-labeled anti-NCA90/95 based granulocyte scan demonstrated reactive bone marrow expansion, splenomegaly and granulocyte infiltration into the tumor. KT293, a S100, gp100 and CD68 positive melanoma cell line derived from an axillary metastasis, produced large amounts of G-CSF in vitro and induced rapidly growing tumors and PLR after subcutaneous inoculation in SCID mice. In contrast to G-CSF-secreting cancer cells of other tissue origin, G-CSF-neutralizing antibodies failed to inhibit the growth of KT293 cells. In addition, KT293 cells did not express G-CSF-receptor. These observations suggest that paracrine effects of G-CSF-secretion and PLR might promote an aggressive melanoma phenotype, as seen in this patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15662134     DOI: 10.4161/cbt.4.1.1447

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  12 in total

Review 1.  Paraneoplastic granulocytosis in metastatic melanoma.

Authors:  Jeremy L Davis; R Taylor Ripley; Timothy L Frankel; Irina Maric; Jay N Lozier; Steven A Rosenberg
Journal:  Melanoma Res       Date:  2010-08       Impact factor: 3.599

2.  Paraneoplastic leukemoid reaction in a patient with BRAF V600E-mutated metastatic malignant melanoma.

Authors:  Emanuel Gouveia; Mónica Sousa; Maria José Passos; António Moreira
Journal:  BMJ Case Rep       Date:  2015-01-09

3.  Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma.

Authors:  Xin-Wen Zhang; Alexander Wald; Martin Salzmann; Niels Halama; Jessica C Hassel
Journal:  Cancer Immunol Immunother       Date:  2022-07-16       Impact factor: 6.630

4.  Multiple Phenotypic Conversion in Malignant Melanoma: Obtainment of Granulocyte Colony-Stimulating Factor-Producing Ability during the Intermission of Nivolumab Therapy.

Authors:  Satomi Chujo; Yoshimasa Nobeyama; Akihiko Asahina; Munenari Itoh
Journal:  Case Rep Oncol       Date:  2022-05-30

5.  Melanoma induced immunosuppression is mediated by hematopoietic dysregulation.

Authors:  Neha Kamran; Youping Li; Maria Sierra; Mahmoud S Alghamri; Padma Kadiyala; Henry D Appelman; Marta Edwards; Pedro R Lowenstein; Maria G Castro
Journal:  Oncoimmunology       Date:  2017-12-14       Impact factor: 8.110

6.  Excessive Leukocytosis Leading to a Diagnosis of Aggressive Thyroid Anaplastic Carcinoma: A Case Report and Relevant Review.

Authors:  Antonis Polymeris; Christina Kogia; Dimitrios Ioannidis; Dimitrios Lilis; Maria Drakou; Nicoletta Maounis; Loukas Kaklamanis; Sofia Tseleni-Balafouta
Journal:  Eur Thyroid J       Date:  2020-04-09

Review 7.  Chronic neutrophilic leukemia: new science and new diagnostic criteria.

Authors:  Natasha Szuber; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-13       Impact factor: 11.037

8.  Gallotannin-rich Caesalpinia spinosa fraction decreases the primary tumor and factors associated with poor prognosis in a murine breast cancer model.

Authors:  Claudia Urueña; Juan Mancipe; John Hernandez; Diana Castañeda; Luis Pombo; Alejandra Gomez; Alexzander Asea; Susana Fiorentino
Journal:  BMC Complement Altern Med       Date:  2013-04-03       Impact factor: 3.659

Review 9.  A role for G-CSF and GM-CSF in nonmyeloid cancers.

Authors:  Alexander M Aliper; Victoria P Frieden-Korovkina; Anton Buzdin; Sergey A Roumiantsev; Alex Zhavoronkov
Journal:  Cancer Med       Date:  2014-04-02       Impact factor: 4.452

10.  Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy.

Authors:  Thilo Gambichler; E Stockfleth; L Susok
Journal:  J Immunother Cancer       Date:  2018-10-30       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.